Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.

Mauri G, Bencardino K, Sartore-Bianchi A, Siena S.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy306. [Epub ahead of print] No abstract available.

PMID:
30060112
2.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F.

Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5.

PMID:
29582224
3.

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.

Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, Di Nicolantonio F.

Gut. 2017 Oct 5. pii: gutjnl-2016-313372. doi: 10.1136/gutjnl-2016-313372. [Epub ahead of print]

4.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

5.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S.

Target Oncol. 2017 Aug;12(4):525-533. doi: 10.1007/s11523-017-0505-6.

6.

Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.

Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G, Nichelatti M, Sartore-Bianchi A, Siena S.

Clin Colorectal Cancer. 2017 Sep;16(3):e153-e163. doi: 10.1016/j.clcc.2017.01.004. Epub 2017 Jan 25. Review.

PMID:
28216246
7.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

8.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.

Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420.

9.

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.

Bencardino K, Mauri G, Amatu A, Tosi F, Bonazzina E, Palmeri L, Querques M, Ravera F, Menegotto A, Boiani E, Sartore-Bianchi A, Siena S.

Clin Colorectal Cancer. 2016 Sep;15(3):213-21. doi: 10.1016/j.clcc.2016.02.001. Epub 2016 Feb 19. Review.

PMID:
26979913
10.

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.

Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S.

Ann Oncol. 2016 Jun;27(6):1062-7. doi: 10.1093/annonc/mdw071. Epub 2016 Feb 24.

PMID:
26916096
11.

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M.

Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9.

12.

Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies.

Notaro P, Dell'Agnola CA, Dell'Agnola AJ, Amatu A, Bencardino KB, Siena S.

Support Care Cancer. 2016 Apr;24(4):1649-54. doi: 10.1007/s00520-015-2952-x. Epub 2015 Sep 26.

PMID:
26408323
13.

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.

Santoro A, Gebbia V, Pressiani T, Testa A, Personeni N, Arrivas Bajardi E, Foa P, Buonadonna A, Bencardino K, Barone C, Ferrari D, Zaniboni A, Tronconi MC, Cartenì G, Milella M, Comandone A, Ferrari S, Rimassa L.

Ann Oncol. 2015 Mar;26(3):542-7. doi: 10.1093/annonc/mdu576. Epub 2014 Dec 23.

PMID:
25538178
14.

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast.

Venturini F, Gambi V, Di Lernia S, Vanzulli A, Bramerio M, Bencardino K, Amatu A, Cipani T, Forti E, Tarenzi E, Sartore-Bianchi A, Pugliese R, Siena S.

J Clin Oncol. 2016 Mar 1;34(7):e54-6. doi: 10.1200/JCO.2013.50.6733. Epub 2014 Jun 30. No abstract available.

PMID:
24982453
15.

Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.

Aprile G, Giuliani F, Cordio S, Sartore-Bianchi A, Bencardino K, Ongaro E, Martines C, Giampieri R, Bordonaro R, Siena S, Cascinu S, Scartozzi M.

Future Oncol. 2014 May;10(7):1125-8. doi: 10.2217/fon.14.54.

16.

Regorafenib in metastatic colorectal cancer.

Sartore-Bianchi A, Zeppellini A, Amatu A, Ricotta R, Bencardino K, Siena S.

Expert Rev Anticancer Ther. 2014 Mar;14(3):255-65. doi: 10.1586/14737140.2014.894887.

PMID:
24559322
17.

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A.

Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947.

18.

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J.

PLoS One. 2013 Nov 11;8(11):e62264. doi: 10.1371/journal.pone.0062264. eCollection 2013.

19.

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

Amatu A, Bencardino K, Sartore-Bianchi A, Siena S.

Ann Transl Med. 2013 Jul;1(2):12. doi: 10.3978/j.issn.2305-5839.2013.01.03. No abstract available.

20.

Colorectal liver metastases: hepatic pedicle clamping during hepatectomy reduces the incidence of tumor recurrence in selected patients. Case-matched analysis.

De Carlis L, Di Sandro S, Giacomoni A, Mihaylov P, Lauterio A, Mangoni I, Cusumano C, Poli C, Tripepi M, Bencardino K.

Eur J Surg Oncol. 2013 Jul;39(7):726-33. doi: 10.1016/j.ejso.2013.03.015. Epub 2013 Apr 18.

PMID:
23601983
21.

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S.

Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518. Epub 2013 Feb 19.

22.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A.

Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.

23.

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.

Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F.

BMC Cancer. 2011 Jun 14;11:247. doi: 10.1186/1471-2407-11-247.

24.

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S1-5. doi: 10.1016/S0305-7372(10)70012-8. Review.

PMID:
21129603
25.

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.

Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M.

Ann Oncol. 2010 Dec;21(12):2382-9. doi: 10.1093/annonc/mdq261. Epub 2010 May 23.

PMID:
20497963
26.

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S.

Target Oncol. 2010 Mar;5(1):19-28. doi: 10.1007/s11523-010-0138-5. Epub 2010 Apr 11. Review. Erratum in: Target Oncol. 2012 Dec;7(4):267.

PMID:
20383783
27.

Flow cytometric detection of circulating endothelial cells and endothelial progenitor cells in healthy subjects.

Mariucci S, Rovati B, Bencardino K, Manzoni M, Danova M.

Int J Lab Hematol. 2010 Feb;32(1 Pt 1):e40-8. doi: 10.1111/j.1751-553X.2008.01105.x. Epub 2008 Oct 16.

PMID:
20088999
28.

Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens.

Manzoni M, Delfanti S, Rovati B, Grasso D, Mariucci S, Bencardino K, Tinelli C, Danova M.

Clin Exp Med. 2010 Jun;10(2):135-8. doi: 10.1007/s10238-009-0072-y. Epub 2009 Oct 10.

PMID:
19821012
29.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.

30.

A six-colour flow cytometric method for simultaneous detection of cell phenotype and apoptosis of circulating endothelial cells.

Mariucci S, Rovati B, Chatzileontiadou S, Bencardino K, Manzoni M, Delfanti S, Danova M.

Scand J Clin Lab Invest. 2009;69(3):433-8. doi: 10.1080/00365510802673175.

PMID:
19140086
31.

Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients.

Collovà E, Rovati B, Grasso D, Bencardino K, Manzoni M, Danova M.

Mol Med Rep. 2009 Jan-Feb;2(1):85-8. doi: 10.3892/mmr_00000066.

PMID:
21475795
32.

Flow cytometric detection of circulating dendritic cells in healthy subjects.

Rovati B, Mariucci S, Manzoni M, Bencardino K, Danova M.

Eur J Histochem. 2008 Jan-Mar;52(1):45-52.

PMID:
18502722
33.

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M.

Ann Oncol. 2008 Apr;19(4):717-23. Epub 2007 Oct 31.

PMID:
17974556
34.

In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer.

Danova M, Bencardino K, Manzoni M, Grasso D, Mariucci S, Rovati B.

Anticancer Res. 2007 Sep-Oct;27(5A):3399-402.

35.

New agents in medical oncology and the risk of venous thromboembolism.

Manzoni M, Bencardino K, Piovella F, Chatzileontiadou S, Delfanti S, Riccardi A, Danova M, Corazza GR.

J Exp Clin Cancer Res. 2007 Jun;26(2):185-94. Review.

PMID:
17725097
36.

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.

Bencardino K, Manzoni M, Delfanti S, Riccardi A, Danova M, Corazza GR.

Intern Emerg Med. 2007 Mar;2(1):3-12. Epub 2007 Mar 31. Review.

37.

Sigmoid colon metastasis from sarcomatoid renal cell carcinoma.

Invernizzi R, Bencardino K, Porta C, Vercelli A, Viglio A, Manzoni M, Sagrada P, Danova M.

Tumori. 2006 May-Jun;92(3):246-8.

PMID:
16869245
38.

Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.

Danova M, Rosti G, De Placido S, Bencardino K, Venturini M.

Oncol Rep. 2005 Dec;14(6):1405-12.

PMID:
16273232
39.

Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.

Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crinò L, Tonato M, Villa E.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6006-12.

40.

Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.

Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E.

Lung Cancer. 2004 May;44(2):231-9.

PMID:
15084388
41.

Mediastinal follicular dendritic cell sarcoma.

Ceresoli GL, Zucchinelli P, Ponzoni M, Gregorc V, Bencardino K, Paties CT.

Haematologica. 2003 Feb;88(2):ECR04. No abstract available.

Supplemental Content

Loading ...
Support Center